Clinical Trials · NCT01931670

A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Name: A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Gonadorelin

Phase: Phase 3
Recruitment status: Completed
Sponsor: AbbVie
Enrollment: 815
Start date: Sep 2013
Locations: See registry
Primary endpoint: Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS)

View Gonadorelin compound reference